Breaking News Instant updates and real-time market news.

AKS

AK Steel

$5.99

-0.1 (-1.64%)

, NUE

Nucor

$54.92

0.32 (0.59%)

06:57
06/19/17
06/19
06:57
06/19/17
06:57

Technical View: U.S. Steel trades higher with peers, analyst action

The stock was last up over 2.5% to $20.67. At that price next resistance is at $22.78. Support is at the prior session closing price of $20.16. Longbow upgraded the stock to Buy as part of a broader upgrade of related names including AK Steel (AKS), Nucor (NUE), and Steel Dynamics (STLD).

AKS

AK Steel

$5.99

-0.1 (-1.64%)

NUE

Nucor

$54.92

0.32 (0.59%)

STLD

Steel Dynamics

$33.18

0.33 (1.00%)

X

U.S. Steel

$20.16

-0.21 (-1.03%)

  • 25

    Jul

AKS AK Steel
$5.99

-0.1 (-1.64%)

04/26/17
JEFF
04/26/17
NO CHANGE
Target $9
JEFF
Buy
AK Steel selloff a buying opportunity, says Jefferies
Jefferies analyst Seth Rosenfeld recommends buying AK Steel following yesterday's post-guidance selloff. The analyst expects the company's results to improve in the second half of 2017 amid lower raw material costs. He reiterates a Buy rating on the shares with a $9 price target.
05/19/17
LBOW
05/19/17
INITIATION
LBOW
Neutral
AK Steel initiated with a Neutral at Longbow
05/25/17
CLKS
05/25/17
UPGRADE
CLKS
Buy
AK Steel upgraded to Buy from Neutral at Clarksons Platou
06/19/17
LBOW
06/19/17
UPGRADE
LBOW
Buy
AK Steel upgraded to Buy from Neutral at Longbow
NUE Nucor
$54.92

0.32 (0.59%)

05/09/17
LBOW
05/09/17
INITIATION
LBOW
Neutral
Nucor initiated with a Neutral at Longbow
05/24/17
FBCO
05/24/17
UPGRADE
Target $68
FBCO
Outperform
Nucor upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Curt Woodworth upgraded Nucor to Outperform and raised his price target for the shares to $68 from $56. The analyst also upgraded his U.S. Steel sector rating to Overweight from Market Weight. He expects prices to recover by late Q3 amid "strong" demand trends, low inventories, and trade dynamics via Section 232 "structurally limiting import flows despite attractive arb spreads." Woodworth notes that U.S. Steel equities have underperformed the market significantly since peaking in February.
05/24/17
05/24/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. DSW (DSW) upgraded to Neutral from Negative at Susquehanna with analyst Sam Poser saying concerns are reflected in valuation. 2. U.S. Steel (X), Steel Dynamics (STLD), and Nucor (NUE) were upgraded to Outperform from Neutral at Credit Suisse. 3. Momo (MOMO) upgraded to Buy from Hold at Deutsche Bank with analyst Eileen Deng saying the company posted accelerating user growth and "impressive" profitability in the first quarter. 4. Tilly's (TLYS) upgraded to Buy from Neutral at B. Riley with analyst Jeff Van Sinderen saying he sees business momentum following the company's first quarter results. 5. Cabot (CBT) upgraded to Buy from Neutral at Northcoast with analyst Kevin Hocevar saying his checks indicate indicate industry conditions are favorable for global carbon black manufacturers over the next few years. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/17
LBOW
06/19/17
UPGRADE
LBOW
Buy
Nucor upgraded to Buy from Neutral at Longbow
STLD Steel Dynamics
$33.18

0.33 (1.00%)

04/24/17
MACQ
04/24/17
UPGRADE
Target $44
MACQ
Outperform
Steel Dynamics upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Aldo Mazzaferro upgraded Steel Dynamics to Outperform and raised its price target to $44 from $38 based on stronger end-market demand driving double-digit volume increases across all product volumes supported by supply tightness, steep tariffs, and low inventory. Mazzaferro raised his 2017/18 earnings estimates to his 2017/18/19 earnings estimates to $3.60/$4.20/$4.60 from $3.00/$3.35/$3.70.
05/24/17
FBCO
05/24/17
UPGRADE
Target $43
FBCO
Outperform
Steel Dynamics upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Curt Woodworth upgraded Steel Dynamics to Outperform and raised his price target for the shares to $43 from $36. The analyst also upgraded his U.S. Steel sector rating to Overweight from Market Weight. The analyst expects prices to recover by late Q3 amid "strong" demand trends, low inventories, and trade dynamics via Section 232 "structurally limiting import flows despite attractive arb spreads." Woodworth notes that U.S. Steel equities have underperformed the market significantly since peaking in February.
06/19/17
LBOW
06/19/17
UPGRADE
LBOW
Buy
Steel Dynamics upgraded to Buy from Neutral at Longbow
X U.S. Steel
$20.16

-0.21 (-1.03%)

06/07/17
06/07/17
UPGRADE

Buy
U.S. Steel upgraded to Buy on valuation at Standpoint Research
As previously reported, Standpoint upgraded U.S. Steel to Buy from Hold with a $28 price target. Analyst Ronnie Moas changed his view saying shares are "undervalued."
06/15/17
COWN
06/15/17
NO CHANGE
Target $21
COWN
Market Perform
Cowen maintains cautious stance on U.S. Steel
Cowen analyst Novid Rassouli met with the new CEO of U.S. Steel and noted the company is focused on achieving asset stability over the next one to two years. However, he continues to see the risk of continued operational issues and thus maintains his cautious stance on the shares. Rassouli maintained his Market Perform rating and $21 price target on U.S. Steel.
06/15/17
AXIO
06/15/17
NO CHANGE
AXIO
U.S. Steel is '2019 story,' says Axiom
After meeting with U.S. Steel's new CEO, Dave Burritt, Axiom analyst Gordon Johnson believes that the company is viewing the next 18-24 months as "a restructuring period" that will feature higher spending on "asset revitalization." The analyst quotes Burritt as saying that he expects Congress to pass a "large bi- partisan infrastructure bill in mid-'18, bearing fruit in '19." Johnson now sees U.S. Steel as a "2019 story," and he warns that the company is likely to miss its $1B 2017 EBITDA guidance due to higher spending on asset revitalization. Johnson keeps a Sell rating on the stock.
06/19/17
LBOW
06/19/17
UPGRADE
LBOW
Buy
U.S. Steel upgraded to Buy from Neutral at Longbow

TODAY'S FREE FLY STORIES

ISBC

Investors Bancorp

$13.41

0.12 (0.90%)

07:49
09/19/17
09/19
07:49
09/19/17
07:49
Conference/Events
Investors Bancorp management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

TGS

Transportadora de Gas del Sur SA

$17.48

0.07 (0.40%)

07:49
09/19/17
09/19
07:49
09/19/17
07:49
Initiation
Transportadora de Gas del Sur SA initiated  »

Transportadora de Gas del…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAM

Pampa Energia S.A.

$60.93

0.2 (0.33%)

07:48
09/19/17
09/19
07:48
09/19/17
07:48
Initiation
Pampa Energia S.A. initiated  »

Pampa Energia S.A. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGS

Progress Software

$37.49

0.18 (0.48%)

07:47
09/19/17
09/19
07:47
09/19/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Progress Software »

Progress:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRGS

Progress Software

$37.49

0.18 (0.48%)

07:47
09/19/17
09/19
07:47
09/19/17
07:47
Hot Stocks
Progress Software 'values' Praesidium's ideas, welcomes input from investors »

In response to a letter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

, AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Hot Stocks
Jacobs Engineering selected by Aerie Pharmaceuticals as engineering contractor »

Jacobs Engineering Group…

JEC

Jacobs Engineering

$56.76

0.81 (1.45%)

AERI

Aerie Pharmaceuticals

$60.10

1.8 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

  • 28

    Feb

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

, AXAHY

AXA

$29.47

0.13 (0.44%)

07:46
09/19/17
09/19
07:46
09/19/17
07:46
Periodicals
BNP weighing tie-up of money-management division with Axa unit, Bloomberg says »

BNP Paribas (BNPQY),…

BNPQY

BNP Paribas

$39.68

0.19 (0.48%)

AXAHY

AXA

$29.47

0.13 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHFC

Chemical Financial

$49.32

0.71 (1.46%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Downgrade
Chemical Financial rating change  »

Chemical Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QSII

Quality Systems

$15.71

-0.14 (-0.88%)

07:45
09/19/17
09/19
07:45
09/19/17
07:45
Initiation
Quality Systems initiated  »

Quality Systems initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/19/17
09/19
07:45
09/19/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: Risk-on…

HOLI

Hollysys

$20.77

0.42 (2.06%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Conference/Events
Hollysys management to meet with Deutsche Bank »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 16

    Oct

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

, AMGN

Amgen

$186.47

-1 (-0.53%)

07:44
09/19/17
09/19
07:44
09/19/17
07:44
Hot Stocks
Cytokinetics doses first patient in Japan in GALACTIC-HF Phase 3 trial »

Cytokinetics announced…

CYTK

Cytokinetics

$14.25

0.1 (0.71%)

AMGN

Amgen

$186.47

-1 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 02

    Dec

  • 03

    Feb

  • 30

    Apr

  • 17

    May

KORS

Michael Kors

$44.65

-0.27 (-0.60%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Technical Analysis
Technical View: Michael Kors moves higher, analyst action »

Shares were last up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INTC

Intel

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Periodicals
Intel Capital invested over $1B in AI-focused companies, TechCrunch says »

Intel has invested more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 05

    Oct

PDCO

Patterson Companies

$37.94

-0.59 (-1.53%)

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Initiation
Patterson Companies initiated  »

Patterson Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$179.98

3.28 (1.86%)

, BSTI

BEST Inc

07:43
09/19/17
09/19
07:43
09/19/17
07:43
Syndicate
BEST Inc cuts size of proposed IPO following 'tepid' response, Reuters reports »

Best Inc (BSTI), a…

BABA

Alibaba

$179.98

3.28 (1.86%)

BSTI

BEST Inc

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

FOLD

Amicus

$13.67

-0.21 (-1.51%)

07:42
09/19/17
09/19
07:42
09/19/17
07:42
Hot Stocks
Amicus granted FDA Fast Track Designation for migalastat »

Amicus Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RAD

Rite Aid

$2.73

0.1 (3.80%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Initiation
Rite Aid initiated  »

Rite Aid initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

MDGL

Madrigal Pharmaceuticals

$19.80

0.99 (5.26%)

07:41
09/19/17
09/19
07:41
09/19/17
07:41
Hot Stocks
Madrigal Pharmaceuticals announces positive outcome from pre-planned DSMB review »

Madrigal Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

MDSO

Medidata

$75.85

-0.01 (-0.01%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Initiation
Medidata initiated  »

Medidata initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

ABX

Barrick Gold

$16.92

-0.38 (-2.20%)

07:40
09/19/17
09/19
07:40
09/19/17
07:40
Conference/Events
Barrick Gold management to meet with Deutsche Bank »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 26

    Oct

07:40
09/19/17
09/19
07:40
09/19/17
07:40
General news
Treasury Market Outlook: yields are a little lower »

Treasury Market Outlook:…

SFTBF

SoftBank

$78.30

0.3501 (0.45%)

07:39
09/19/17
09/19
07:39
09/19/17
07:39
Periodicals
SoftBank Ventures Korea looks to invest in promising start-ups, CNBC says »

SoftBank Ventures Korea,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCK

McKesson

$148.42

-1.46 (-0.97%)

07:38
09/19/17
09/19
07:38
09/19/17
07:38
Initiation
McKesson initiated  »

McKesson initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

SUPN

Supernus

$49.65

0.6 (1.22%)

07:37
09/19/17
09/19
07:37
09/19/17
07:37
Downgrade
Supernus rating change  »

Supernus downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.